The use of 5-ALA in glioma surgery: mechanism of action, clinical benefits, and technical limitations: a narrative review
Aims: Glioblastoma is the most aggressive primary brain tumor, characterized by rapid proliferation and diffuse infiltration into surrounding brain tissue. Maximal safe resection is a critical prognostic factor, yet complete tumor removal remains difficult. This review aims to synthesize current data on the application of 5-aminolevulinic acid (5-ALA) in glioma surgery, with particular emphasis on its mechanism of action, clinical utility, limitations, and integration with other intraoperative imaging techniques. Methods: A narrative review was conducted using the PubMed and Google Scholar databases. The search included combinations of keywords such as "5-ALA," "5-aminolevulinic acid," "glioblastoma," "high-grade glioma," and "neurosurgery." Peer-reviewed English-language articles were selected to examine the clinical and technical aspects of 5-ALA-guided fluorescence imaging in glioma resection. No time restriction or formal inclusion criteria were applied. Results: 5-ALA induces selective fluorescence in malignant glioma tissue, enabling improved intraoperative visualization and facilitating gross total resection. Studies have demonstrated enhanced surgical outcomes, including prolonged progression-free and overall survival in patients undergoing 5-ALA-guided resection. However, limitations include reduced sensitivity in low-grade gliomas, the risk of false-positive or false-negative signals, and dependency on specialized equipment and optical conditions. Adjunctive use with intraoperative MRI and sodium fluorescein has shown preliminary benefits. Off-label applications in non-glioma tumors are under investigation. Conclusions: 5-ALA represents a clinically validated tool for improving tumor delineation and surgical precision in high-grade glioma surgery. Despite certain limitations, especially in low-fluorescence tumors and deep-seated lesions, future research into combined imaging strategies, enhanced metabolic targeting, and photodynamic applications may broaden its clinical utility.
Authors
- Aleksandra Reda
- M Wasik (ORCID: https://orcid.org/0009-0000-6788-024X)
- Magdalena Cyrkler (ORCID: https://orcid.org/0009-0003-5721-6945)
- Aleksandra Krygowska (ORCID: https://orcid.org/0000-0002-6860-9942)
- Dorota Słupik
- Kamila Sieradocha
- Aleksandra Maria Śledziewska (ORCID: https://orcid.org/0009-0006-3782-9201)
- Aleksandra Zagajewska (ORCID: https://orcid.org/0009-0001-8610-0234)
- Aleksandra Giba (ORCID: https://orcid.org/0009-0003-2384-1662)
Publication Details
- Journal
- Archiv Euromedica
- Published
- 2025-08-29
- DOI
- https://doi.org/10.35630/2025/15/4.013
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00